Publications by authors named "Irma Oving"

Claim this Profile
H
How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.
Daniela E Oprea-Lager, Tessa van Elst, Shafak Aluwini, Els Dewulf, Henk van der Poel, Irma M Oving

Eur Urol Open Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer.
Sandra van Wilpe, Davide Croci, Sara S Fonseca Costa, Iris Baw Te Paske, Sofie H Tolmeijer, Irma M Oving

JCI Insight· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Sofie H Tolmeijer, Sandra van Wilpe, Maartje J Geerlings, Daniel von Rhein, Tineke J Smilde, Irma M Oving

Eur Urol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Dianne Bosch, Kim J M van der Velden, Irma M Oving, Dirk N J Wyndaele, Leo E Weijs

J Nucl Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
Maarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, Jean-Paul van Basten, Frederiek Terheggen

Prostate Cancer Prostatic Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Irma Oving

Eur Urol Open Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.
Marieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, David Bertwistle, Laura McDonald, Irma M Oving

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, Gerald W Verhaegh, Anton F J de Haan, Irma M Oving

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, Gerald W Verhaegh, Onno van Hooij, Irma M Oving

Mol Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
Anna van der Voort, Mette S van Ramshorst, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper, Irma M Oving

JAMA Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.
Shafak S Aluwini, Niven Mehra, Martijn P Lolkema, Daniela E Oprea-Lager, Derya Yakar, Irma Oving

Eur Urol Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper, Irma M Oving

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Mette S van Ramshorst, Erik van Werkhoven, Aafke H Honkoop, Vincent O Dezentjé, Irma M Oving

Breast· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcription factor achaete scute-like 2 controls intestinal stem cell fate.
Laurens G van der Flier, Marielle E van Gijn, Pantelis Hatzis, Pekka Kujala, Andrea Haegebarth, Irma Oving

Cell· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Intestinal Wnt/TCF Signature.
Laurens G Van der Flier, Jacob Sabates-Bellver, Irma Oving, Andrea Haegebarth, Mariagrazia De Palo

Gastroenterology· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector.
Marc van de Wetering, Irma Oving, Vanesa Muncan, Menno Tjon Pon Fong, Helen Brantjes

EMBO Rep· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.
Marc van de Wetering, Elena Sancho, Cornelis Verweij, Wim de Lau, Irma Oving

Cell· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular causes of colon cancer.
Irma M Oving, Hans C Clevers

Eur J Clin Invest· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis